64B Stock Overview
PhenomeX Inc. operates as a functional cell biology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PhenomeX Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$0.93 |
| 52 Week Low | US$0.84 |
| Beta | 0.94 |
| 1 Month Change | 4.78% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 64B | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.02% | 0.1% | 0.3% |
| 1Y | n/a | -5.3% | 6.9% |
Return vs Industry: Insufficient data to determine how 64B performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how 64B performed against the German Market.
Price Volatility
| 64B volatility | |
|---|---|
| 64B Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 64B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 64B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 285 | Siddhartha Kadia | phenomex.com |
PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease.
PhenomeX Inc. Fundamentals Summary
| 64B fundamental statistics | |
|---|---|
| Market cap | €95.00m |
| Earnings (TTM) | -€118.74m |
| Revenue (TTM) | €68.48m |
1.4x
P/S Ratio-0.8x
P/E RatioIs 64B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 64B income statement (TTM) | |
|---|---|
| Revenue | US$71.82m |
| Cost of Revenue | US$25.32m |
| Gross Profit | US$46.50m |
| Other Expenses | US$171.03m |
| Earnings | -US$124.53m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 64.75% |
| Net Profit Margin | -173.40% |
| Debt/Equity Ratio | 0% |
How did 64B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/04 21:25 |
| End of Day Share Price | 2023/09/29 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PhenomeX Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Goparaju | Berenberg |
| Mark Massaro | BTIG |
| Tycho Peterson | J.P. Morgan |